Brain Tumor Clinical Trials

For Newly-Diagnosed Patients

Immunotherapy and Radiation Therapy for Newly Diagnosed Glioblastoma

Designed for patients who are newly diagnosed with MGMT-unmethylated glioblastoma, this phase II/III study tests the use of immunotherapy drugs ipilimumab and nivolumab – which may help the body’s immune system attack cancer cells – in conjunction with radiation therapy.

For Newly-Diagnosed Patients

Adding SurVaxM Vaccine Therapy to Standard of Care Chemotherapy

Patients with newly-diagnosed glioblastoma may be eligible to participate in this phase II study examining the use of standard of care temozolomide chemotherapy combined with SurVaxM – an immunotherapeutic vaccine – compared to temozolomide alone.

For Patients with Recurrent Glioblastoma

Immunotherapy for Recurrent Glioblastoma

This phase II study examines immunotherapy drugs ipilimumab and nivolumab in patients with glioblastoma that has recurred and carries a high number of mutations. These immunotherapy medications with monoclonal antibodies may help the body's immune system attack cancerous cells and may interfere with tumor cells’ ability to grow and spread.

For Patients with Recurrent Glioblastoma

Chemotherapy Drug Berubicin for Recurrent Glioblastoma

This phase II study further evaluates the use of investigational chemotherapy drug berubicin in patients with recurrent glioblastoma whose standard first line therapy was unsuccessful. The U.S. Food and Drug Administration granted berubicin Fast Track designation in July 2021.

For Patients with Newly-Diagnosed or Recurrent Glioblastoma

Combining Selinexor and Standard of Care Therapy

This phase I/II study examines the use of the oral drug selinexor in combination with standard of care therapy – which may include radiation, chemotherapy, targeted therapy or a tumor treatment device. The study is open to patients with newly-diagnosed or recurrent glioblastoma.

Genetic-Guided Treatment for Brain Metastases

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. These brain metastases often have altered or mutated genes. Medications that target these genes may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Inhibitor Drug Therapy for Progressive Meningiomas

Designed for patients with meningiomas that are growing, spreading or getting worse, this phase II trial studies the efficacy of inhibitor drugs that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.